Proton Beam Therapy for Advanced Periocular Skin Cancer: An Eye-Sparing Approach.

IF 4.4 2区 医学 Q1 ONCOLOGY Cancers Pub Date : 2025-01-20 DOI:10.3390/cancers17020327
Yingying Zhang, Isabela C S Lima, Alessandra A Woo, Stephen Zieminski, Judith A Adams, Megan A Hughes, Annie W Chan
{"title":"Proton Beam Therapy for Advanced Periocular Skin Cancer: An Eye-Sparing Approach.","authors":"Yingying Zhang, Isabela C S Lima, Alessandra A Woo, Stephen Zieminski, Judith A Adams, Megan A Hughes, Annie W Chan","doi":"10.3390/cancers17020327","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives:</b> The management of periocular skin malignancies presents a unique challenge. Proton beam therapy, due to its sharp dose fall-off, allows for the delivery of a tumoricidal dose to the tumor while sparing adjacent normal tissues. <b>Methods:</b> Thirteen patients with a median age of 76.5 years received protons at our institution to a median dose of 66.6 Gy (RBE). Sixty-four percent of the lesions were basal cell carcinoma, and 22% were squamous cell carcinoma. Eighty-six percent of patients underwent biopsy only or partial resection. Fifty-seven percent of the lesions were located in the medial or lateral canthus. There was orbital invasion in 93% of the cases. Locoregional control probability and overall survival were estimated with the Kaplan-Meier method. Treatment toxicity was scored using the CTCAE 4.0. <b>Results:</b> At a median follow-up of 96 months, there was no local recurrence. The rate of orbital preservation was 100%. Functional vision was maintained in all the patients. There was no acute or late grade 3 or higher toxicity. <b>Conclusions:</b> Protons allow for long-term tumor control with eye preservation in patients with locally advanced periocular skin cancers. Larger prospective multi-institutional trials with standardized ophthalmological assessments are needed to confirm our findings.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 2","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764392/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers17020327","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/Objectives: The management of periocular skin malignancies presents a unique challenge. Proton beam therapy, due to its sharp dose fall-off, allows for the delivery of a tumoricidal dose to the tumor while sparing adjacent normal tissues. Methods: Thirteen patients with a median age of 76.5 years received protons at our institution to a median dose of 66.6 Gy (RBE). Sixty-four percent of the lesions were basal cell carcinoma, and 22% were squamous cell carcinoma. Eighty-six percent of patients underwent biopsy only or partial resection. Fifty-seven percent of the lesions were located in the medial or lateral canthus. There was orbital invasion in 93% of the cases. Locoregional control probability and overall survival were estimated with the Kaplan-Meier method. Treatment toxicity was scored using the CTCAE 4.0. Results: At a median follow-up of 96 months, there was no local recurrence. The rate of orbital preservation was 100%. Functional vision was maintained in all the patients. There was no acute or late grade 3 or higher toxicity. Conclusions: Protons allow for long-term tumor control with eye preservation in patients with locally advanced periocular skin cancers. Larger prospective multi-institutional trials with standardized ophthalmological assessments are needed to confirm our findings.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
质子束疗法治疗晚期眼周皮肤癌:保眼疗法
背景/目的:眼周皮肤恶性肿瘤的治疗是一个独特的挑战。质子束治疗,由于其剂量急剧下降,允许在不影响邻近正常组织的情况下向肿瘤提供杀瘤剂量。方法:13例中位年龄为76.5岁的患者在我院接受了中位剂量为66.6 Gy (RBE)的质子治疗。64%的病变为基底细胞癌,22%为鳞状细胞癌。86%的患者只接受活检或部分切除。57%的病变位于内眦或外眦。93%的病例有眼眶侵犯。用Kaplan-Meier法估计局部区域控制概率和总生存率。采用CTCAE 4.0对治疗毒性进行评分。结果:中位随访96个月,无局部复发。眼眶保存率为100%。所有患者均保持功能性视力。没有急性或晚期3级或更高的毒性。结论:质子治疗可以长期控制局部晚期眼周皮肤癌患者的肿瘤并保护眼睛。需要更大规模的前瞻性多机构试验和标准化的眼科评估来证实我们的发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancers
Cancers Medicine-Oncology
CiteScore
8.00
自引率
9.60%
发文量
5371
审稿时长
18.07 days
期刊介绍: Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
期刊最新文献
RETRACTED: Chen et al. LncRNA ERVH48-1 Contributes to the Drug Resistance of Prostate Cancer and Proliferation through Sponging of miR-4784 to the Activation of the Wnt/β-Catenin Pathway. Cancers 2023, 15, 1902. Supramaximal Resection in Glioblastoma: Expanding Surgical Boundaries in the Era of Precision Neuro-Oncology-A Systematic Review. Immunohistochemical Expression of IDO and PD-L1 in Distinct Compartments of Breast Cancer Tissue: Correlation with Clinicopathological Features and Outcomes. Comparison of Comprehensive Serum miRNA Sequencing and Apolipoprotein A2 Isoforms for Early Detection of Pancreatic Cancer. Integrating Artificial Intelligence into Breast Cancer Histopathology: Toward Improved Diagnosis and Prognosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1